Skip to Content

Managing Risks with Newer Oral Small Molecules in Patients with IBD

What are the risks of treating inflammatory bowel diseases (IBD) with small oral molecules, JAK inhibitors, and Sphingosine-1-phosphate receptor modulators, and how should they be managed? In this MEDtalk, Dr. Parakkal Deepak presents his insights, published in a recent article in Current Gastroenterology Reports. He especially highlighted major adverse cardiac events and the importance of discussing this with patients.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top